UK To Test Third Vaccine Dose In Immunocompromised People
Data From OCTAVE Study Show Low Response In 40% Of Patients After Two Doses
Executive Summary
Initial results of the OCTAVE DUO study are expected later this year and will feed into the UK’s deployment of COVID-19 vaccines in people with weakened immune systems.
You may also be interested in...
Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
Drug Over-Use & Industry’s Carbon Footprint Targeted In English Review
New recommendations could result in more effective prescribing and fewer adverse events.
Coronavirus Notebook: UK Rolls Out Ronapreve To Hospitalized Patients, Drug Safety Unit Reviews mRNA Vaccine Heart Inflammation Link
Pressure is growing on richer countries to share their excess vaccine doses, and the European Parliament has passed legislation intended to strengthen the EU’s health security framework and make joint vaccine procurement more transparent.